Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NAUTILUS BIOTECHNOLOGY, INC.

(NAUT)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-30 pm EST
1.930 USD   -3.02%
01/26Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
GL
01/26Nautilus Biotechnology Expands to San Diego
GL
01/26Nautilus Biotechnology Expands to San Diego
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/24/2023 01/25/2023 01/26/2023 01/27/2023 01/30/2023 Date
1.82(c) 1.88(c) 1.97(c) 1.99(c) 1.93 Last
247 200 278 439 80 135 189 842 90 416 Volume
-1.09% +3.30% +4.79% +1.02% -3.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -62,1 M - -
Net cash position 2022 205 M - -
P/E ratio 2022 -3,86x
Yield 2022 -
Sales 2023 0,13 M - -
Net income 2023 -85,4 M - -
Net cash position 2023 125 M - -
P/E ratio 2023 -2,86x
Yield 2023 -
Capitalization 241 M 241 M -
EV / Sales 2022 -
EV / Sales 2023 870x
Nbr of Employees 127
Free-Float 72,5%
More Financials
Company
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its platform end-to-end solution comprised of... 
More about the company
Ratings of Nautilus Biotechnology, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about NAUTILUS BIOTECHNOLOGY, INC.
01/26Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results ..
GL
01/26Nautilus Biotechnology Expands to San Diego
GL
01/26Nautilus Biotechnology Expands to San Diego
AQ
01/26Nautilus Biotechnology Expands to San Diego
CI
01/20Nautilus Biotechnology Partners with the Translational Genomics Research Institute to I..
AQ
01/19Nautilus Biotechnology, Translational Genomics Research Institute Team Up to Advance St..
MT
01/19Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGe..
GL
01/19Nautilus Biotechnology, Inc. Partners with the Translational Genomics Research Institut..
CI
2022Nautilus Biotechnology Launches 'First Access Challenge'
AQ
2022Nautilus Biotechnology Launches “First Access Challenge”
GL
2022Nautilus Biotechnology Launches “First Access Challenge”
AQ
2022NAUTILUS BIOTECHNOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
AQ
2022Transcript : Nautilus Biotechnology, Inc., Q3 2022 Earnings Call, Nov 01, 202..
CI
2022Nautilus Biotechnology, Inc. Appoints Karen Akinsanya to Nominating Committee
CI
2022Nautilus Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
More news
News in other languages on NAUTILUS BIOTECHNOLOGY, INC.
01/26Nautilus Biotechnology s'étend à San Diego
01/19Nautilus Biotechnology et l'Institut de recherche en génomique translationnelle font éq..
01/19Nautilus Biotechnology, Inc. s'associe au Translational Genomics Research Institute (Tg..
2022Nautilus Biotechnology, Inc. nomme Karen Akinsanya au comité de nomination
2022Nautilus Biotechnology, Inc. annonce ses résultats financiers pour le troisième trimest..
More news
Analyst Recommendations on NAUTILUS BIOTECHNOLOGY, INC.
More recommendations
ETFs positioned on NAUTILUS BIOTECHNOLOGY, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Defiance NextGen SPAC Derived ETF - USD0.1%-0.37%-NC
IShares Nasdaq US Biotechnology (D) - USD0.03%1.83%United_States
IShares Nasdaq US Biotechnology - USD0.03%1.78%United_States
IShares Micro-Cap ETF - USD0.03%1.46%United_States
Invesco Nasdaq Biotechnology ETF - USD0.03%1.11%-United_States
More ETFs positioned on NAUTILUS BIOTECHNOLOGY, INC.
Chart NAUTILUS BIOTECHNOLOGY, INC.
Duration : Period :
Nautilus Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NAUTILUS BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 1,93 $
Average target price 5,00 $
Spread / Average Target 159%
EPS Revisions
Managers and Directors
Sujal M. Patel President, CEO, Secretary & Director
Anna Mowry Chief Financial Officer & Treasurer
Matthew L. Posard Director
Parag Mallick Director & Chief Scientist
Mary E. Godwin Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NAUTILUS BIOTECHNOLOGY, INC.10.56%248
MODERNA, INC.5.42%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.64%28 465
SEAGEN INC.9.46%26 117